Background-Restenosis is the major drawback of percutaneous coronary interventions involving excessive activation and proliferation of vascular smooth muscle cells (SMCs). The nuclear receptor Nurr1 is an early response gene known mainly for its critical role in the development of dopamine neurons. In the present study, we investigated Nurr1 in human and experimental vascular restenosis. Methods and Results-In a prospective cohort of 601 patients undergoing percutaneous coronary intervention, including stent placement, we found a strong association between Nurr1 haplotypes and in-stent restenosis risk. Furthermore, Nurr1 is specifically expressed in human in-stent restenosis and induced in cultured human SMCs in response to serum or tumor necrosis factor-␣. Lentivirus-mediated gain-and loss-of-function experiments in SMCs demonstrated that overexpression of Nurr1 inhibited proliferation, consistent with increased expression of the key cell-cycle inhibitor p27 Kip1 , whereas Nurr1 silencing enhanced SMC growth. The tumor necrosis factor-␣-induced proinflammatory response of SMCs is inhibited by Nurr1, as reflected by reduced interleukin-1␤, tumor necrosis factor-␣, and monocyte chemoattractant protein-1 expression. Consistent with our in vitro data, endogenous Nurr1 reduced wire injury-induced proliferation and vascular lesion formation in carotid arteries of ApoE Ϫ/Ϫ mice. Conclusion-Nurr1 haplotypes are associated with human restenosis risk, and Nurr1 is expressed in human in-stent restenosis. In SMCs, Nurr1 inhibits proliferation and inflammatory responses, which explains the inhibition of SMC-rich lesion formation in mice. The recently identified small-molecule drugs that enhance the activity of Nurr1 reveal this nuclear receptor as an attractive novel target for (local) intervention in restenosis.
D espite technological and pharmacological advances, patients undergoing percutaneous coronary intervention (PCI) still develop (in-stent) restenosis, requiring repeat revascularization procedures. 1 Several lines of evidence indicate that genetic factors may explain the increased risk of restenosis independently of conventional clinical and procedural parameters. 2 Genetic variations identifying patients at increased risk for restenosis will lead to improved risk stratification and eventually to patient-tailored therapy (eg, to rationalize the choice of either a bare metal stent or drugeluting stent). In addition, genetic variations that are associ-ated with restenosis may indicate that the protein encoded by the variable gene is functionally involved and clinically relevant in this process.
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Restenosis can develop within months after PCI. 3 The underlying mechanism of this pathology involves endothelial denudation and mechanical injury of the vessel wall, which enhances inflammatory cell recruitment, ultimately driving excessive smooth muscle cell (SMC) activation and proliferation. 4 As a result, the end-stage vascular lesion in (in-stent) restenosis is composed predominantly of SMCs and is referred to as an SMC-rich vascular lesion. The application of sirolimus or paclitaxel drug-eluting stents has reduced the incidence of in-stent restenosis (ISR) considerably. 1, 5 These drugs effectively inhibit SMC proliferation but also hinder effective reendothelialization and may delay arterial healing, pathophysiological processes implicated in (late) in-stent thrombosis, a potentially fatal complication. 6, 7 In the present study, we generated knowledge on the nuclear "orphan" receptor Nurr1 (also called NR4A2 or NOT), which is classified as part of the NR4A subfamily of nuclear receptors, which also includes Nur77 and NOR-1. The nuclear receptor superfamily comprises ligand-activated receptors such as liver X receptors and peroxisomeproliferator-activated receptors, as well as receptors like Nurr1, for which ligands have not been identified. 8 The transcription factor Nurr1 interacts as a monomer or homodimer with consensus response elements to promoters of target genes, 9 but it can also form heterodimers with retinoid X receptors to mediate retinoid responses. 10 In addition to direct binding to the promoter of target genes, Nurr1 modulates gene transcription by transrepression of other transcription factors. 11, 12 So far, the transcription factor Nurr1 has been associated mainly with brain development, which is in line with the absence of dopaminergic neurons in Nurr1 knockout mice. 13 Other studies showed that Nurr1 not only is essential in the development of mesencephalic dopamine neurons and maintenance of their function but also may play a role in the pathogenesis of Parkinson disease and related disorders. 14 In neuronal microglia and macrophages, Nurr1 regulates inflammatory responses; we have described differential expression of Nurr1 in human atherosclerotic lesions compared with normal, healthy human arteries. 12, 15 In addition, Nurr1 has been described in rheumatoid arthritis. 16 The expression of Nurr1 in human restenosis and the function of Nurr1 in SMCs in vascular lesion formation have not yet been described.
In this study, we report that a haplotype-defined variation of the Nurr1 gene is associated with coronary ISR risk in PCI patients and that Nurr1 is expressed in human coronary in-stent restenotic lesions. We demonstrate that Nurr1 has an antiproliferative and antiinflammatory function in human cultured SMCs and protects against arterial wire injuryinduced SMC-rich lesion formation in mice.
Methods
A detailed description of materials and methods is available in the online-only Data Supplement.
Study Population, Follow-Up, and Study End Points
The study was approved by the local research and ethics committee and conforms to the Declaration of Helsinki. Patients were included in a single-center, prospective observational cohort after successful bare metal stent placement in a native coronary artery for stable angina. Patients returned for follow-up angiography between 6 and 12 months after stent placement. Quantitative coronary analysis was performed as described. 17 Clinical follow-up at 1 year was obtained. The primary end points of this study were angiographic binary ISR (Ͼ50% diameter stenosis) and late lumen loss in minimal luminal diameter at follow-up. The secondary end points were target lesion revascularization (TLR), repeat PCI, nonfatal myocardial infarction, coronary artery bypass grafting, or death or the combined end point of major adverse cardiac events (MACEs). TLR was defined as repeat revascularization of the stented segment or within 5-mm margins proximal or distal to the stent by either repeat PCI or coronary artery bypass grafting.
Genotyping and Statistical Analysis of the Genetic Association Study
The haplotype-tagging single-nucleotide polymorphism (ht-SNP) selection of the Nurr1 gene has been described. 18 Genotypes were determined with the Taqman assay (Applied Biosystems, Foster City, Calif). Reactions were performed with the Taqman-Prism7900HT in 384-well format. Associations between individual SNPs and ISR, repeat PCI, TLR, and MACE were examined with Cox proportional-hazard models with SPSS-16.0 for Windows (SPSS Inc, Chicago, Ill). From the obtained unphased SNP genotype data, haplotype frequencies and their effects on risk of ISR, repeat PCI, TLR, or MACE were estimated with weighted Cox regression as described. 19 Variables depicted by Cox proportional-hazard analysis to be predictive for ISR, repeat PCI, TLR, or MACE (PϽ0.05) and known predictive variables were entered into the model (control of confounding). We adjusted for multiple testing with the Bonferroni correction. When correcting for multiple testing across outcomes, we considered a value of PϽ0.013 to be significant, whereas we considered a value of PϽ0.004 to be significant when adjusting across outcomes and haplotypes. Event-free survival curves were calculated by Kaplan-Meier analysis; differences between the groups were calculated with the log-rank statistic. Values of PϽ0.05 were considered statistically significant.
Human Tissue Specimens and In Situ Hybridization
Human tissue samples were obtained from patients undergoing coronary atherectomy for ISR according to protocols approved by the medical ethics committee of our institute. Radioactive in situ hybridization was performed with gene-specific probes as described. 20
SMC Culture, DNA Synthesis, Western Blotting, and Quantitative Reverse-Transcription Polymerase Chain Reaction
SMCs were explanted from human umbilical cord arteries or mouse aortas. DNA synthesis was monitored by 5-bromo-2-deoxyuridine (BrdU) incorporation according to the manufacturer's protocol (Roche, Basel, Switzerland). Lentiviruses that contain human Nurr1 complementary DNA or short-hairpin (sh) human or mouse Nurr1 sequences and their appropriate controls, empty or scrambled shRNA virus, respectively, were generated. For Western blotting, p27 Kip1 , Nurr1, and ␣-tubulin primary antibodies were used. ␣-Tubulin staining served as the loading control. SMCs were stimulated with 25 ng/mL tumor necrosis factor-␣ (TNF␣; R&D Systems, Minneapolis, Minn). Inflammatory gene expression was analyzed by quantitative reverse-transcription polymerase chain reaction. Experiments were performed in duplicate with 3 distinct SMC isolates.
Mouse Model of Arterial Wire Injury, Lentiviral Transduction, and Immunohistochemistry
Female ApoE Ϫ/Ϫ mice, 9 to 10 weeks old, were fed a Western-type diet containing 0.25% cholesterol and 15% cacao butter (SDS, Sussex, UK) starting 1 week before surgery. Plasma cholesterol levels were determined at 0, 1.5, 3, and 4 weeks during the experiment, and no differences were observed between treatment groups. All animal work was approved by regulatory authorities of Leiden University and complied with Dutch government guidelines. Mice were anesthetized, and wire injury of the left common carotid artery was performed as described previously. [21] [22] [23] For lentiviral transfer, the carotid artery was incubated for 15 minutes (10 8 IU per mouse supplemented with 10 g/mL DEAE-dextran) directly after wire injury. Animals were euthanized at 7 days or 4 weeks after injury, and carotids were taken out and embedded in paraffin. For BrdU incorporation, animals were injected with 62.5 g/g BrdU at days 2, 3, and 6. For morphometry, elastic laminae were visualized in 10 sections (250 m apart) by Lawson staining (Leica Qwin, Bensheim, Germany). Experiments were performed with 7 to 9 animals per group.
Statistical Analyses of In Vitro and Animal Experiments
The Mann-Whitney 2-tailed U test was used to calculate the statistical significance of cell culture and animal experiments. Data are reported as median (Ϯrange). Values of PϽ0.05 were considered statistically significant (*PϽ0.05, **PϽ0.01, ***PϽ0.001 in the figures).
Results

Nurr1 Genotypes and Haplotypes Are Associated With Angiographic and Clinical ISR Risk
A total of 601 patients were included in the study; clinical follow-up was obtained in 600 patients, and angiographic follow-up was performed in 597 patients. Failure rates of genotyping for Nurr1 SNP A, Ϫ15906TϾA (rs1466408); SNP B, Ϫ3413TϾC (rs13428968); and SNP C, ϩ7275GϾT (rs12803), were 3.7%, 6.2%, and 1.2%, respectively. These 3 SNPs cover the linkage disequilibrium block that comprises the entire Nurr1 gene ( Figure 1A and 1B). All genotype distributions were in Hardy-Weinberg equilibrium (PϾ0.05; Table I of the online-only Data Supplement), and their genotype and allele frequencies were comparable to those reported in the National Center for Biotechnology Information SNP database for white populations. Haplotype reconstruction resulted in 4 haplotypes with frequencies Ͼ1% of the study population ( Figure 1C ). The clinical and angiographic baseline characteristics of the patients are listed in Table 1 and were tested for differences between the 3 single ht-SNPs. No significant differences were detected except for hypertension in SNP B (Pϭ0.027) ( Table II of 
the onlineonly Data Supplement).
The primary end points of ISR and late lumen loss and the secondary end points of TLR, repeat PCI, and MACE risk were analyzed for the comprehensive haplotypes. Hazard ratios (HRs) for the primary and secondary study end points for the individual ht-SNPs after Cox regression analyses are shown in Table III of the online-only Data Supplement. Haplotype 1 (TTG) was most frequent in our study population (52.4%; Figure 1C ) and served as the reference haplotype. Haplotype 3, which contains the minor alleles of SNP B and C (TCT), and haplotype 4, which contains the minor alleles of SNP A and C (ATT), were associated with a significantly increased ISR, TLR, repeat PCI, and MACE risk compared with the reference haplotype 1 (HR between 1.6 and 3.1 for all end points; Table 2 , model 1). This association persisted after multivariable adjustment, including age, gender, hypertension, smoking, diabetes mellitus, statin use, stent length, and length of stenosis in the model (HR between 1.7 and 3.4 for all end points; Table 2 , model 2, and Figure 2A ). After Bonferroni correction for multiple testing across outcomes, haplotype 3 remained significantly associated with increased ISR risk, whereas haplotype 4 remained significantly associated with increased ISR, TLR, repeat PCI, and MACE risk (PϽ0.013). Even after adjustment for multiple testing across haplotypes and outcomes, haplotype 4 re-mained associated with all of these outcomes. To further illustrate the increased risk of these 2 haplotypes, we performed Kaplan-Meier analysis of event-free survival. Significantly lower ISR, repeat PCI, TLR, and MACE event-free survival were detected in patients having 1 or 2 copies of haplotypes 3 and 4 ( Figure 2B ). In addition, cumulative late lumen loss in noncarriers of the risk haplotypes 3 and 4 was significantly lower than that of carriers of the risk haplotypes 3 and 4 (mean late loss, 0.9Ϯ0.6 versus 1.1Ϯ0.7 mm for noncarriers and carriers of risk haplotypes 3 and 4, respectively; Pϭ0.001; Figure 2C ).
Nurr1 Is Expressed in Human ISR
Because we observed such a strong association of Nurr1 genotypes with ISR, we analyzed gene expression of Nurr1 in human ISR. Coronary ISR specimens of 9 patients were obtained and analyzed for Nurr1 expression by radioactive in situ hybridization (see Table V of the online-only Data Supplement for patient characteristics). In accordance with previous studies, immunohistochemical analyses demonstrated that SMCs are the main cell type in human in-stent restenotic lesions ( Figure 3A) , with a relatively low number of macrophages ( Figure 3B ). 24 Previously, we have shown that Nurr1 is not expressed in normal media of human arteries. 20 Here, we demonstrate that Nurr1 messenger RNA (mRNA) is strongly expressed in ISR lesions ( Figure 3C ) in specimens derived from distinct patients showing a scattered expression pattern ( Figure 3D and 3E). In each of the 9 different specimens analyzed, we observed substantial expression of Nurr1 in 36Ϯ6% of the cells.
Nurr1 Inhibits Proliferation of Human SMCs
To reveal the function of Nurr1 in restenosis, we assayed whether Nurr1 modulates SMC proliferation, a process of critical importance in (in-stent) restenosis. 4 In cultured human SMCs, Nurr1 mRNA is induced by FCS with optimal mRNA expression levels 2 hours after treatment ( Figure I Left circumflex 111 (19) Restenotic lesion, n (%) 76 (13) Chronic total occlusion lesion, n (%) 197 (33) Figure 4B ). 25 Consistent with these data, Nurr1 overexpression reduces DNA synthesis 1.6- Table IV of the online-only Data Supplement). fold ( Figure 4C ), whereas knockdown of endogenous Nurr1 increases DNA synthesis 1.9-fold ( Figure 4D) as measured by BrdU incorporation. From these data, we conclude that Nurr1 inhibits SMC proliferation involving enhanced expression of p27 Kip1 .
Nurr1 Reduces Inflammatory Gene Expression in SMCs
Because inflammation is causally involved in (in-stent) restenotic lesion formation, we analyzed the expression and function of Nurr1 in SMCs in this process. 26 First, we studied the expression of Nurr1 in human SMCs in response to the proinflammatory cytokine TNF␣ and showed that Nurr1 mRNA is induced Ͼ50-fold with optimal expression 1 hour after stimulation ( Figure 5A ). SMCs showed a strong induction of several proinflammatory cytokines and chemokines in response to TNF␣, most significantly interleukin (IL)-1␤, TNF␣, and monocyte chemoattractant protein-1 (MCP-1; Figure 5B ), and IL6 and IL8 (data not shown). Nurr1 overexpression substantially inhibits TNF␣-induced expression of IL1␤ (2.9-fold), TNF␣ (1.6-fold), and MCP-1 (2.0fold; Figure 5C ) but does not change IL6 and IL8 expression (data not shown). In line with these data, shRNA-mediated knockdown of endogenous Nurr1 revealed a 3.7-fold increased expression of TNF␣, whereas IL1␤ and MCP-1 expression levels were not changed ( Figure 5D ).
Nurr1 Is a Key Regulator of Vascular Lesion Formation After Arterial Injury in ApoE ؊/؊ Mice
On the basis of our observation that Nurr1 is expressed in human ISR and recognition of the inhibitory effect of Nurr1 on SMC proliferation and inflammatory gene expression in vitro, we hypothesized that Nurr1 attenuates vascular lesion formation. To test this hypothesis, we performed targeted gain-and loss-of-function studies in an arterial wire injurybased restenosis model in ApoE Ϫ/Ϫ mice. [21] [22] [23] In mice transduced locally with lentivirus encoding human Nurr1, the transgene was detected in medial SMCs by radioactive in situ hybridization ( Figure 6A ). shRNA directed against murine Nurr1 resulted in a 5.4-fold reduction in endogenous Nurr1 expression in murine SMCs ( Figure III of the online-only Data Supplement). Consecutive sections of the lesions were analyzed by Lawson staining and SMCspecific immunohistochemistry. (Figure 6B ). Quantitative morphometric analyses demonstrated that medial surface area and external elastic lamina area ( Figure 6C and 6D) were comparable between all groups. Overexpression of Nurr1 resulted in a significant 3.6-fold reduction in neo-intimal area compared with control and a 1.4-fold reduction in neointima/media ratio. In line with these data, Nurr1 knockdown resulted in a trend toward an increase in neointimal area compared with control (Pϭ0.27) and increased neointima/media ratio (Pϭ0.15) ( Figure 6E and 6F). Nurr1 knockdown resulted in a significant 1.8-fold increase in lumen stenosis compared with control, whereas Nurr1 overexpression decreased lumen stenosis 2.0-fold (Pϭ0.31; Figure 6G ). In line with our in vitro data, 2.5-fold more p27 kip1 -positive cells were observed compared with control (Pϭ0.04), whereas Nurr1 knockdown resulted in a 4.4-fold decrease in p27 kip1 -positive cells (Pϭ0.01; Figure 6H ). On the basis of our in vitro observations, Nurr1 was predicted to influence inflammatory cell recruitment and proliferation in vivo, especially at the onset of lesion formation. We therefore investigated these processes 7 days after injury; quantitative morphometric analyses revealed no significant differences in lesion size between the groups (see Figure IV of the online-only Data Supplement). Consecutive sections of these early lesions were analyzed for proliferation (BrdU incorporation) and inflammatory cell recruitment (Mac3) ( Figure 7A ), T lymphocytes (CD3), or neutrophils (mAb7/4) (data not shown). At this early stage, proliferating cells were detected in the media and neointima. In the adventitia, low numbers of T lymphocytes and neutrophils (maximum, 2 to 10 cells per section) were detected, and no differences between the different mouse groups were found. Quantitative analysis of BrdU incorporation revealed that mice overexpressing Nurr1 showed no difference, whereas Nurr1 knockdown resulted in a 2.0-fold increase in BrdUpositive cells compared with control (Pϭ0.020). Knockdown of Nurr1 enhances inflammatory cell recruitment 2.8-fold (Pϭ0.039). These data underscore the importance of endogenous Nurr1 in the inhibition of proliferation and inflammatory cell recruitment at this early stage of lesion formation ( Figure 7B and 7C ). 
Discussion
In this study on nuclear receptor Nurr1, we identified common genetic variation of the Nurr1 gene as an independent predictor of angiographic and clinical ISR risk in PCI patients. Haplotypes 3 (TCT) and 4 (ATT), inferred by combining 3 individual ht-SNPs, are associated with increased angiographic restenosis, TLR, repeat PCI, and MACE risk compared with the reference haplotype 1 (TTG), which contains the common alleles of all 3 ht-SNPs. Haplotypes 3 and 4 contain the minor alleles of SNP B and A, respectively, and because both of these ht-SNPs are localized in the promoter region of the Nurr1 gene, it may be reasoned that these genetic variations reflect SNPs in this region that affect expression levels of Nurr1. Furthermore, we demonstrate high expression levels of the nuclear receptor Nurr1 in human coronary ISR and show that overexpression of Nurr1 reduces SMC-rich lesion formation on wire injury in ApoE Ϫ/Ϫ mice. Decreased lesion formation is explained by Nurr1-mediated inhibition of proliferation of SMCs and by attenuation of the inflammatory response of these cells. Thus, although increased expression of Nurr1 is observed in activated SMCs and vascular lesions, we have demonstrated here that Nurr1 has an antiproliferative and antiinflammatory function in SMCs and vascular lesion formation, supporting the hypothesis that Nurr1 is crucially involved in a negative feedback mechanism to restrain excessive SMC proliferation in restenosis.
The inflammatory response of SMCs in vascular disease, including restenosis, has gained far less attention compared with the role of proliferation and migration of these cells in this pathology. Our data underpin the importance of the secretion of SMCs of proinflammatory cytokines and chemokines such as MCP-1 that accelerate recruitment of inflammatory cells into the vessel wall. 21, 27 We revealed strong induction of Nurr1 expression in SMCs in response to TNF␣, and significantly, Nurr1 reduces expression of IL1␤, TNF␣, and MCP-1 in SMCs, indicating that this nuclear receptor provokes a negative feedback regulation on the inflammatory response of SMCs. Indeed, in macrophages, we have demonstrated that Nurr1 also inhibits the inflammatory response, which is in line with the identification of Nurr1 in a genome-wide screen as an inhibitor of nuclear factor-B in monocytes. 15, 28 Recently, in neuronal microglia, transrepression of nuclear factor-B has been demonstrated to be responsible for the antiinflammatory properties of Nurr1. 12 Nurr1 overexpression in neuronal dopaminergic MN9D cells results in G1 cell-cycle arrest, which is controlled by cyclin-dependent kinases, including p27 Kip1 . 29 In accordance with the growth inhibitory function of Nurr1 in neuronal cells, we detected reduced proliferation and increased protein expression of p27 Kip1 in SMCs overexpressing Nurr1. Multiple studies using human vascular tissue and animal models have provided evidence that p27 Kip1 , a cyclin-dependent kinase inhibitor, is a key regulator of SMC proliferation in restenosis. 25, 30 We therefore conclude that the enhanced p27 Kip1 expression in response to Nurr1 may, at least partially, explain its antiproliferative effect.
To study the in vivo function of Nurr1 in SMC-rich neointima formation, we applied the wire injury model in ApoE Ϫ/Ϫ mice that models human restenosis because their SMC-rich neointimal lesions develop in an atherosclerosisprone background like in patients who suffer from atherosclerosis and are treated invasively with PCI. 22, 23 Furthermore, SMCs are infected predominantly by the recombinant virus as the wire disrupts the overlaying endothelial cell layer. Therefore, this approach allowed us to specifically establish the protective function of Nurr1 in SMCs in neointima formation relevant to human restenosis.
Structural analyses of the C-terminal domain of Nurr1 revealed that the classic ligand-binding cavity is filled with hydrophobic and aromatic amino acid side chains and that an atypical coactivator cleft is exposed on the surface. 31, 32 With this finding taken into account, it is remarkable that smallmolecule drugs have been identified that enhance the transcriptional activity of Nurr1. [33] [34] [35] [36] [37] So far, these Nurr1 activators have been considered potential drugs for enhancing dopaminergic neuron function in Parkinson disease. The data presented in this study suggest that (local) application of these Nurr1 activators may also prevent SMC-rich vascular lesion formation.
Conclusions
We revealed that common variations of the Nurr1 gene are associated with ISR, TLR, and repeat PCI risk in patients undergoing PCI in combination with placement of a bare metal stent. In line with these data, we detected the expression of Nurr1 in human ISR and demonstrated that Nurr1 reduces SMC proliferation and inflammatory responses and inhibits vascular lesion formation. We therefore propose Nurr1 as a novel potential therapeutic target in the prevention of (in-stent) restenosis and other proliferation-and inflammation-driven vascular diseases. 
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